c AN3365 (MIC 50/90 , 0.5/1 g/ml) was active against Enterobacteriaceae, including a subset of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains (MIC 50/90 , 1/2 g/ml). AN3365 inhibited 98.0 and 92.2% of wild-type (MIC 50/90 , 2/8 g/ml) and carbapenem-resistant (MIC 50/90 , 4/8 g/ml) Pseudomonas aeruginosa strains, respectively, at <8 g/ml. AN3365 also demonstrated activity against wild-type Acinetobacter baumannii (MIC 50/90 , 2/8 g/ml) and Stenotrophomonas maltophilia (MIC 50/90 , 2/4 g/ml), while it was less active against multidrug-resistant A. baumannii (MIC 50/90 , 8/16 g/ml) and Burkholderia cepacia (MIC 50/90 , 8/32 g/ml).
A
ntimicrobial resistance has been recognized as a major threat to human health worldwide, since resistance rates have increased considerably during the past 2 decades among hospitaland community-acquired pathogens (1) . Several agents directed against Gram-positive bacteria have been approved for clinical use in the last decade (2) . While linezolid and daptomycin are novel agents with a broad spectrum of activity against Gram-positive organisms, ceftaroline and telavancin are improved analogues of known scaffolds. However, Gram-negative bacteria represent a serious issue in hospital settings and are currently responsible for 40 to 60% of all acquired pneumonias, approximately 70% of urinary tract infections (UTI), and 23 to 30% of bacteremias in intensive care unit (ICU) patients (3); the currently available therapeutic options for treating these infections have become limited due to the emergence and dissemination of antibacterial resistance (4) (5) (6) (7) .
In addition to increasing prevalence rates of nosocomial infections caused by antimicrobial-resistant Gram-negative bacteria, the number of new Gram-negative antimicrobial agents in development has been limited (6) . Moreover, the treatment of these infections has become challenging due to a substantial increase of complex multidrug resistance patterns exhibited by these organisms (3, 8) . These phenotypic patterns are conferred by a combination of extended-spectrum ␤-lactamase (ESBL) enzymes, carbapenemases, drug molecule modifications, target site alterations, and decreased drug permeability (3, 5, 8, 9) . Furthermore, recently discovered mechanisms not only confer resistance to specific drugs within a class but also encode resistance to entire classes of antimicrobial agents, such as the metallo-␤-lactamases (MBL), serine carbapenemases (Klebsiella pneumoniae carbapenemase [KPC]), and 16S rRNA methylases, whose coding sequences are often located on broad-host-range plasmids (10) (11) (12) (13) (14) (15) .
More recently, a new class of antibacterial agents possessing a novel mechanism of action has been developed. These new compounds belong to a boron-based class of antibiotics, namely, the aminomethyl benzoxaboroles, which inhibit the bacterial leucyltRNA synthetase (LeuRS), essential for protein synthesis (16) . The LeuRS enzyme provides a proofreading mechanism during the translation process (17) . AN3365, the lead analogue compound within this new class, has shown preliminary in vitro activity when tested against Enterobacteriaceae and Pseudomonas aeruginosa strains (17) . In this study, the in vitro activities of AN3365 and comparator agents against contemporary collections of wild-type and multidrug-resistant (MDR) clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli (NF-GNB) were evaluated.
A total of 2,029 Enterobacteriaceae (2006 to 2009) and 252 NF-GNB (74.0% from 2006 to 2008) clinical isolates were included in this study. Overall, isolates were mainly from North America (49.2%) and Europe (45.9%); a small percentage of organisms originated from Latin America (4.7%) and the Asia-Pacific region (Ͻ0.1%). Strains were selected according to wild-type and MDR phenotypes from previously characterized collections from JMI Laboratories (North Liberty, IA). Among non-wild-type Enterobacteriaceae, isolates included were those with stably derepressed AmpC, those with AmpC whose gene is plasmid borne (pAmpC), and those that produce ESBL and carbapenemase enzymes (KPC and OXA-48). Isolates with pAmpC-encoding genes were characterized by PCR and sequencing. All ESBL-producing strains had a previous positive confirmatory ESBL testing result (18) with or without molecular characterization of the ␤-lactamase-encoding gene, while KPC and OXA-48 producers were detected by PCR and sequencing (19) (20) (21) (22) (23) . NF-GNB included P. aeruginosa (a total of 101 strains, among which 51 were carbapenem resistant [19 MBL producers] ) (13, (24) (25) (26) (27) (28) (29) (30) , Acinetobacter baumannii (a total of 51, among which 26 were MDR strains [i.e., resistant to at least three antimicrobial classes]) (31, 32) , Stenotrophomonas maltophilia (50 wild-type strains), and Burkholderia cepacia (50 wildtype strains).
Isolates were tested for susceptibility by the broth microdilu-tion method using 96-well frozen-form panels with cation-adjusted Mueller-Hinton broth (fresh-frozen media) according to the Clinical and Laboratory Standards Institute (CLSI) recommendations (33 CTX-M-15 strains), except for one KPC-3-producing E. coli strain. All ESBL E. coli strains exhibited ceftazidime and ceftriaxone MIC results of Ն2 g/ml and were imipenem susceptible (MIC, Յ1 g/ml), except for the KPC-3-producing isolate (ceftazidime, ceftriaxone, and imipenem MIC values, Ն16 g/ml). E. coli isolates were equally susceptible to AN3365 (MIC 50/90 , 0.5/1 g/ml) and polymyxin B (MIC 50/90 , 0.5/1 g/ml; 97.6% susceptible), which demonstrated MIC results 4-fold higher than imipenem (MIC 50/90 , 0.12/0.25 g/ml; 96.6% susceptible) and tigecycline (MIC 50/90 , 0.25/0.5 g/ml; 100.0% susceptible).
The phenotypic distribution of the selected 261 K. pneumoniae isolates was as follows: wild type, 60.9%; those bearing pAmpC, 1.9% (two CMY-2 and three FOX-5 strains; ceftazidime and ceftriaxone MIC, Ն8 g/ml); ESBL, 27.2% (ceftazidime and ceftriaxone MIC, Ն2 g/ml); carbapenemase, 10.0% (KPC producers; ceftazidime, ceftriaxone, cefepime and imipenem MIC, Ն4 g/ml) ( Table 1 ). All 71 ESBL-producing K. pneumoniae strains had a positive confirmatory phenotypic testing result, with genotypic results available for 29 (40.8%) isolates, of which 8 were CTX-M-like, 2 OXA-2-like, 2 OXA-10-like, 2 OXA-48-like, 5 SHV-5, 1 SHV-7, 3 SHV-12, 1 SHV-30, 4 SHV-31, and 1 SHV-40. Overall, AN3365 (MIC 50/90 , 0.5/1 g/ml), imipenem (MIC 50/90 , 0.25/1 g/ml; 90.0% susceptible), tigecycline (MIC 50/90 , 0.5/2 g/ ml; 88.5 to 96.2% susceptible), and polymyxin B (MIC 50/90 , 0.5/2 g/ml; 95.8% susceptible) demonstrated highest in vitro activity when tested against all K. pneumoniae isolates. However, when a further analysis was performed against a subset of KPC-producing K. pneumoniae strains, only AN3365 (MIC 50/90 , 1/2 g/ml) ( Table  1 ) and tigecycline (MIC 50/90 , 1/2 g/ml; 80.8 to 92.3% susceptible) (data not shown) retained activity.
The selected Enterobacter sp. isolates (250 Enterobacter aerogenes strains and 252 Enterobacter cloacae strains) were mostly wild-type strains (78.1%; ceftazidime and ceftriaxone MIC results of Յ4 and Յ1 g/ml, respectively), while other isolates exhibited elevated MIC values (Ն8 g/ml) for ceftazidime and ceftriaxone. Overall, AN3365 (MIC 50/90 , 0.5/1 g/ml) was as active as levofloxacin (MIC 50/90 , Յ0.5/1 g/ml; 90.4% susceptible), gentamicin (MIC 50/90 , Յ0.5/1 g/ml; 97.6 to 98.4% susceptible), and tigecycline (MIC 50/90 , 0.5/1 g/ml; 95.6 to 98.8% susceptible) against E. aerogenes. These drugs showed MIC 50/90 results at least 2-fold lower than that for imipenem (MIC 50/90 , 1/2 g/ml; 62.4 to 98.4% susceptible) when tested against E. aerogenes species. The E. cloacae isolates were most susceptible to AN3365 (MIC 50/90 , 0.5/1 g/ ml), levofloxacin (MIC 50/90 , Յ0.5/1 g/ml; 90.9 to 93.3% susceptible), imipenem (MIC 50/90 , 0.5/1 g/ml; 94.8 to 99.6% susceptible), and tigecycline (MIC 50/90 , 0.5/1 g/ml; 92.5 to 96.0% susceptible). Other agents, such as ceftazidime (77.2 to 80.2% susceptible), piperacillin-tazobactam (78.0 to 84.9% susceptible), and polymyxin B (83.3 to 86.8% susceptible) demonstrated suboptimal coverage against tested Enterobacter spp. (Table 2 ).
The majority of Citrobacter freundii (74.3%) isolates were considered wild type (ceftazidime and ceftriaxone MICs of Յ4 and Յ1 g/ml, respectively), whereas other isolates (25.7%) belong-ing to this species exhibited higher MIC values for these drugs (Table 1 ). This collection of C. freundii isolates was very susceptible (susceptibility rates Ն 91.3% [CLSI] ) to several comparator agents tested, such as cefepime (MIC 50/90 , Յ1/2 g/ml), imipenem (MIC 50/90 , 1/1 g/ml), levofloxacin (MIC 50/90 , Յ0.5/2 g/ ml), gentamicin (MIC 50/90 , 1/1 g/ml), tigecycline (MIC 50/90 , 0.5/1 g/ml), and polymyxin B (MIC 50/90 , 0.5/1 g/ml). AN3365 (MIC 50/90 , 0.5/1 g/ml) exhibited MIC results lower than or similar to MICs of these agents (Table 2) .
Most P. mirabilis strains (235/250; 94.0%) included in the study demonstrated a wild-type phenotype of resistance to selected cephalosporins (ceftazidime and ceftriaxone), while the (Table 1 ). AN3365 exhibited low MIC 50/90 values (0.5/0.5 g/ml) when tested against S. marcescens; the values were similar to those obtained for imipenem (MIC 50/90 , 0.5/1 g/ml; 94.8% susceptible [CLSI] ). Other comparators, such as cefepime (MIC 50/90 , Յ1/2 g/ml; 99.2% susceptible), levofloxacin (MIC 50/90 , Յ0.5/2 g/ ml; 93.3% susceptible), gentamicin (MIC 50/90 , 1/2 g/ml; 92.1% susceptible), and tigecycline (MIC 50/90 , 1/2 g/ml; 97.6% susceptible), also demonstrated overall good in vitro activity against these strains (Table 2) .
Wild-type P. aeruginosa clinical isolates were susceptible (Ն92.0%; CLSI criteria) to the comparator agents tested, except for piperacillin-tazobactam (86.0% susceptible) and ceftazidime (88.0% susceptible) (Table 3) . Imipenem (MIC 50/90 , 1/2 g/ml), levofloxacin (MIC 50/90 , Յ0.5/2 g/ml), and gentamicin (MIC 50/90 , 1/4 g/ml) showed the lowest MIC 50/90 values when tested against wild-type P. aeruginosa, followed by AN3365 (MIC 50/90 , 2/8 g/ml) and cefepime (MIC 50/90 , 2/8 g/ml). The last two were 2-to 4-fold more active than the antipseudomonal agents piperacillin-tazobactam (MIC 50/90 , 4/32 g/ml) and ceftazidime (MIC 50/90 , 4/16 g/ml). AN3365 demonstrated MIC 50/90 values of 4/8 g/ml (Tables 1 and 3 ) when tested against carbapenem-resistant P. aeruginosa. In contrast, all comparator agents tested showed elevated MIC 50 (Ն16 g/ml) and MIC 90 (Ն32 g/ml) results and high antimicrobial resistance rates (Ն44.0%) against carbapenem-resistant P. aeruginosa (Table 3) .
When tested against wild-type Acinetobacter spp., AN3365 (MIC 50/90 , 2/8 g/ml), piperacillin-tazobactam (MIC 50/90 , Յ0.06/8 g/ml), ceftazidime (MIC 50/90 , 8/16 g/ml), and cefepime (MIC 50/90 , 2/8 g/ml) showed similar MIC 90 values, while other agents exhibited lower results (Table 3 ). In contrast, MDR Acinetobacter sp. isolates were more resistant (11.5 to 100.0%) to the comparator drugs tested, and the most active compounds were AN3365 (MIC 50/90 , 8/16 g/ml) and tigecycline (MIC 50/90 , 2/8 g/ml) ( Table 3 ). Among antimicrobial agents tested against S. maltophilia, tigecycline (MIC 50/90 , 0.5/1 g/ml) demonstrated the lowest MIC results, while AN3365 (MIC 50/90 , 2/4 g/ml) and levofloxacin (MIC 50/90 , 1/4 g/ml; 86.0% susceptible) recorded equivalent in vitro potencies against this species ( (Table 3) .
AN3365 (MIC 50/90 , 0.5/1 g/ml) demonstrated potent activity against Enterobacteriaceae, inhibiting all isolates at Յ2 g/ml, except for one Proteus vulgaris strain (MIC, 4 g/ml). Furthermore, the overall MIC distribution of AN3365 remained constant (MIC 50 , 0.5 g/ml) across the tested Enterobacteriaceae species, groups of organisms, and resistant subsets. However, slightly higher AN3365 MIC results were observed for P. mirabilis isolates (MIC 50/90 , 1/1 g/ml), suggesting that this species may be less susceptible to this compound than other wild-type strains. In addition, KPC-producing K. pneumoniae strains also exhibited higher MIC 50 results (1 g/ml) than the respective susceptible counterparts. This resistant subset was exclusively represented by MDR strains, against which AN3365 retained in vitro activity, where monotherapy does not represent a current option (36, 37) . Importantly, Enterobacteriaceae strains possessing several characterized mechanisms of resistance to ␤-lactam agents were similarly susceptible to AN3365, suggesting absence of cross-resistance, which was expected since this compound belongs to a novel boron-based benzoxaborole class (17) .
The MIC AN3365 results against NF-GNB clinical isolates were less uniform. However, AN3365 demonstrated MIC 50 results of 2 to 4 g/ml for P. aeruginosa and inhibited 89.5 to 93.8% of resistant subsets at Յ8 g/ml, which included MBL-producing strains. Carbapenem-resistant P. aeruginosa strains included in this study had an MDR phenotype, likely due a complex combination of several resistance mechanisms, such as upregulation of AmpC and efflux pump systems, downregulation of outer membrane proteins, and lastly expression of MBL (9) . Strains possessing decreased permeability, affecting the activity of several classes of antimicrobial agents, are often detected among cystic fibrosis patients (38) , and the data reported here suggest that these resistance mechanisms do not make a significant impact on the cellular penetration of AN3365.
The mortality risk attributed to infections caused by A. baumannii isolates have remained controversial (4); however, the increased prevalence of MDR strains is irrefutable (8, 31, 32, 35, 39) . AN3365 inhibited 92.2% of A. baumannii strains at Յ8 g/ml, although it required a slightly higher drug concentration (16 g/ ml) to inhibit a similar percentage (96.2%) of an MDR subset (Table 1 ). However, it should be noted that these data were obtained from a small collection of 51 A. baumannii strains. Conversely, AN3365 (MIC 50/90 , 2/4 g/ml) had good in vitro activity against intrinsic ␤-lactam-resistant isolates of S. maltophilia, inhibiting all but two isolates at Յ4 g/ml. Only levofloxacin and tigecycline demonstrated in vitro activity against S. maltophilia. The AN3365 results obtained against S. maltophilia are encouraging since the prevalence of this species among hospitalized patients has increased during the last few decades and since infections caused by this MBL-encoding gene-bearing species have led to inappropriate empirical therapy and consequently increased mortality (7, 40) .
The in vitro results presented here indicate that AN3365 and/or analogues belonging to this novel class of antibiotic agents may be an option for managing difficult-to-treat infections caused by MDR Gram-negative organisms. However, despite the potent in vitro activity described here, emergence of resistance was observed e Tigecycline breakpoints approved by the FDA for Enterobacteriaceae (Յ2 g/ml for susceptible; Ն8 g/ml for resistance) were applied for comparison purposes (35) .
